gamma-Lumicolchicine is three, alpha, beta, and gamma isomers of ultraviolet degradation products of colchicine that lack many of the physiological actions of the parent; used as experimental control for colchicine actions.
Trimethylcolchicinic acid methyl ether (HAN 76504), an antimitotic agent, blocks microtubule assembly by attaching to tubulin and inhibiting its polymerization. It enhances tubulin's intrinsic GTPase activity, induces apoptosis across various normal and tumor cell lines, and activates the JNK SAPK pathway. Currently unnamed, it is referred to by a provisional code name in line with MedKoo Chemical Nomenclature (https: www.medkoo.com page naming) for ease of communication.
Malformin C is a natural fungus-derived bicyclic pentapeptide that has antibacterial properties, particularly against species of Bacillus. Malformin C potently blocks the ability of bleomycin to induce G2 arrest in human T-cell leukemia-derived Jurkat cells (IC50 = 0.9 nM). It less potently abrogates colchicine-induced M phase arrest in Jurkat cells (IC50 = 24 nM). Malformin C inhibits cell growth dose-dependently in Colon 38 and HCT 115 cancer cells (IC50s = 0.27 and 0.18 μM, respectively) but has a low therapeutic index against cancer xenografts when tested in mice.
MY-875 is a potent microtubulin polymerization inhibitor that competes at colchicine binding sites, exhibiting an IC50 value of 0.92 μM. It effectively suppresses microtubulin polymerization, exerting its inhibitory effect. Additionally, MY-875 exerts its biological impact by activating the Hippo pathway, inducing apoptosis, and displaying commendable anticancer activity [1].